Gadeta aims to develop a cancer treatment for all types of tumors
Employees: 11-50
Total raised: $7.9M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Utrecht Ho... | utrechthol... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.03.2016 | Series A | $7.9M | - |
Mentions in press and media 2
| Date | Title | Description |
| 02.12.2022 | Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors | Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions Agreement combines Gadeta's gamma delta tar... |
| 29.03.2016 | Gadeta Completes €7M Series A Funding | Gadeta B.V., a Utrecht, The Netherlands-based startup focused on the discovery and development of novel cancer immunotherapies based on gamma delta (γδ) T cell receptors, completed a €7m Series A funding. The round was led by Baxalta Ventur... |